UBS Group’s AN2 Therapeutics ANTX Stock Holding History
Bought
Maintained
Sold
Other funds holding ANTX
ACA
UBS Group's ANTX Position: Q3 2026 in Review
UBS Group increased its AN2 Therapeutics (ANTX) stake by 240% in Q3 2026, buying an estimated $940K and bringing the position to 251,686 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #5390.
UBS Group first reported a position in ANTX in Q1 2022 and has held it in 17 quarters since. 88 funds tracked by Wall St. Rank hold ANTX as of Q3 2026.
- UBS Group held 251,686 shares of AN2 Therapeutics worth $1.34M as of Q3 2026.
- UBS Group bought 177,600 AN2 Therapeutics shares in Q3 2026, an estimated $940K.
- AN2 Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #5390 holding.
- UBS Group first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 17 quarters since.
- 88 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.